Patents Assigned to Array Biopharma Inc.
  • 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors
    Patent number: 9328091
    Abstract: Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: May 3, 2016
    Assignees: GENENTECH, INC., ARRAY BIOPHARMA INC.
    Inventors: Anna Leivers, Josef R. Bencsik, James F. Blake, Martin F. Hentemann, Nicholas C. Kallan, Jun Liang, Ian S. Mitchell, Stephen T. Schlachter, Eli M. Wallace, Rui Xu, Tony P. Tang
  • Process for making hydroxylated cyclopentylpyrimidine compounds
    Patent number: 9309204
    Abstract: The invention provides new processes for making and purifying hydroxylated cyclopenta[d]pyrimidine compounds, which are useful for the treatment of diseases such as cancer as AKT protein kinase inhibitors, including the compound (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: April 12, 2016
    Assignees: ARRAY BIOPHARMA INC., GENENTECH, INC.
    Inventors: Jonathan W. Lane, Travis Remarchuk, Sagar Shakya, Keith L. Spencer, Peter J. Stengel
  • Substituted piperazines as AKT inhibitors
    Patent number: 9303040
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: April 5, 2016
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik
  • Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride
    Patent number: 9278936
    Abstract: Provided herein is a hydrogen chloride salt of 1-(3-/t?r/-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea, crystalline forms of 1-(3-½^butyl-1^-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride, processes for the preparation of said crystalline forms, pharmaceutical compositions containing a crystalline form of 1-(3-r<i/-r-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride Form B, processes for the preparation of said compositions, pharmaceutical compositions prepared by said methods, and the use of said compositions in the treatment of various diseases and disorders.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: March 8, 2016
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: Alisha B. Arrigo, Donald T. Corson, Coralee G. Mannila
  • Serine/threonine kinase inhibitors
    Patent number: 9259470
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: February 16, 2016
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 9242964
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: January 26, 2016
    Assignees: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert M. Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • Preparation of and formulation comprising a MEK inhibitor
    Patent number: 9238627
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: January 19, 2016
    Assignees: Array BioPharma, Inc., Novartis AG
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20160002232
    Abstract: Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Application
    Filed: September 18, 2015
    Publication date: January 7, 2016
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Mark Laurence Boys, Robert Kirk DeLisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marmsater, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
    Publication number: 20160002210
    Abstract: Provided herein are novel processes for preparing a compound of Formula (I) to the use of said compound as an intermediate in novel processes for the synthesis of indazole derivatives, and to indazole intermediates and derivatives prepared by the processes described herein.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 7, 2016
    Applicant: Array BioPharma Inc.
    Inventors: Todd C. Eary, Bruno P. Hache, Derrick Juengst, Stacey Renee Spencer, Peter J. Stengel, Daniel John Watson
  • Method of treatment using substituted imidazo[1,2B]pyridazine compounds
    Patent number: 9227975
    Abstract: Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 5, 2016
    Assignee: Array BioPharma, Inc.
    Inventors: Steven W. Andrews, Julia Haas, Yutong Jiang, Gan Zhang
  • Mitotic kinesin inhibitors and methods of use thereof
    Patent number: 9221841
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: December 29, 2015
    Assignee: Array BioPharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Shelley Allen, Ellen Laird, Joseph P. Lyssikatos, John E. Robinson, Christopher P. Corrette, Robert Kirk DeLisle, Walter C. Voegtli
  • Substituted quinazolines as serine/threonine kinase inhibitors
    Patent number: 9187462
    Abstract: Compounds having the formula (I) wherein R1, R2, R3 and Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: November 17, 2015
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Huifen Chen, Mark Joseph Chicarelli, Jason Demeese, Rustam Ferdinand Garrey, John Gaudino, Lewis Gazzard, Robert J. Kaus, Samuel Kintz, Peter J. Mohr, David A. Moreno, Jacob Schwarz, Christopher S. Siedem, Eli M. Wallace
  • PYRROLOPYRIDINES AS KINASE INHIBITORS
    Publication number: 20150322061
    Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: January 7, 2015
    Publication date: November 12, 2015
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Yvan Le Huerou, James F. Blake, Indrani W. Gunawardana, Peter J. Mohr, Eli M. Wallace, Bin Wang, Mark Joseph Chicarelli, Michael Lyon
  • Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
    Patent number: 9174981
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: November 3, 2015
    Assignee: Array BioPharma Inc.
    Inventors: Mark Laurence Boys, Robert Kirk DeLisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marmsater, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
    Patent number: 9168254
    Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: October 27, 2015
    Assignee: Array BioPharma Inc.
    Inventors: Donald T. Corson, Christopher M. Lindemann, Daniel J. Watson
  • CRYSTALLINE FORMS OF (1S)-1-[5-(AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL
    Publication number: 20150299182
    Abstract: The present invention relates to crystalline polymorph forms of (1S)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol, to pharmaceutical compositions comprising such crystalline polymorph forms, and to processes for preparing them. The invention further relates to methods of treatment of diabetes related disorders comprising administering such solid-state forms or compositions thereof to a subject, and to use of such crystalline polymorph forms in the manufacture of medicaments.
    Type: Application
    Filed: November 8, 2013
    Publication date: October 22, 2015
    Applicants: Amgen Inc., Array BioPharma Inc.
    Inventors: Sylvie Asselin, Lisa Brett, Ying Chen, Donald T. Corson, Andrew Cosbie, Robert Farrell, Indrani W. Gunawardana, Jinkun Huang, Jonathan W. Lane, Dennis Lei, Christopher M. Lindemann, Van Luu, Coralee G. Mannila, Robert Milburn, Henry Morrison, Helming Tan, Jason Tedrow, Daniel J. Watson
  • Hydrogen sulfate salt
    Patent number: 9156795
    Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: October 13, 2015
    Assignees: Array BioPharma, Inc., Astrazeneca AB
    Inventors: John DeMattei, Tsung-Hsun Chuang, Christopher John Squire, Ronald John Roberts, Gorkhn Sharma-Singh, Mohammed Pervez, James Gair Ford, Richard Anthony Storey, Paul Alfred Dickinson
  • Method of treatment using checkpoint kinase 1 inhibitors
    Patent number: 9155726
    Abstract: Methods of treating cancer by administering a DNA damaging agent and a CHK1 Inhibitor on a dosing regimen are provided.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: October 13, 2015
    Assignee: Array BioPharma Inc.
    Inventors: Michael J. Humphries, Shannon L. Winski
  • Serine/threonine kinase inhibitors
    Patent number: 9133187
    Abstract: Compounds having the formula I wherein Z, Z1 Z2 Z3, R3a, R3b and Rb and as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: September 15, 2015
    Assignees: ARRAY BIOPHARMA INC., GENENTECH, INC.
    Inventors: James F. Blake, Huifen Chen, Mark Joseph Chicarelli, Jason Demeese, Rustam Garrey, John J. Gaudino, Robert J. Kaus, Gabrielle R. Kolakowski, Allison L. Marlow, Peter J. Mohr, Li Ren, Jacob Schwarz, Christopher S. Siedem, Allen A. Thomas, Eli Wallace, Steven Mark Wenglowsky, Steven Boyd
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 9126940
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: September 8, 2015
    Assignees: VentiRx Pharmaceuticals, Inc., Array Biopharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang